Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07167862 · ClinicalTrials.gov registry record · Phase 4

Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

A Phase 4 study, sponsored by University of California, Irvine.

Not yet
Registry status
Phase 4
Development phase
96
Enrollment target

NCT07167862: Clinical Trial Phase 4 study, sponsored by University of California, Irvine.

NCT07167862 is a Phase 4 study that has not yet begun recruiting, run by University of California, Irvine. The registered enrollment target is 96 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07167862, a Phase 4 study, has not yet begun recruiting, sponsored by University of California, Irvine.

NOT YET RECRUITING
Registry status
Phase 4
Development phase
96 participants
Enrollment target

Study Summary

This study explores a novel approach to improving care for postpartum patients with preeclampsia, a pregnancy-related condition characterized by high blood pressure, protein in the urine, and organ dysfunction. Preeclampsia affects up to 9% of pregnancies and can progress to include complications of seizures, stroke, and even death. Over 60% of patients with preeclampsia continue to experience high blood pressure at the time of discharge from their delivery hospitalization, and many of these patients require blood pressure medications for up to 6 months postpartum. Even with blood pressure medications, many of these patients are readmitted to the hospital within six weeks of delivery. In this study, the investigators will utilize point-of-care ultrasound (POCUS), a quick and non-invasive, bedside imaging strategy, to look for signs of excess fluid accumulating in the lungs and venous system of postpartum patients with preeclampsia. Because excess fluid has the potential to worsen blood pressure, subjects with evidence of this on POCUS would be treated with a diuretic medication called furosemide (either orally or intravenously) within 24 hours of delivery. The investigators' main goal is to determine whether using POCUS can help physicians make better treatment decisions and improve short-term outcomes for postpartum patients with preeclampsia. The investigators' aim to achieve faster recovery of blood pressure, reduce the need for blood pressure medication at hospital discharge, and lower the rates of hospital readmission for those with preeclampsia. This study could significantly enhance the overall care and health of postpartum patients.

Primary Outcome

Persistent hypertension at time of postpartum hospital discharge, defined both as blood pressure \> 140/90 mm Hg according to American College of OB/GYN (ACOG) guidelines and 130/80 mm Hg according to Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-9) guidelines

Interventions

  • DRUG Oral furosemide
  • DIAGNOSTIC_TEST Butterfly iQ3 ultrasound system for determination of postpartum volume status
  • DRUG Intravenous furosemide

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2026-06-15
Est. Completion 2028-06-15
Phase Phase 4
University of California, Irvine

368 total trials

What is known before NCT07167862 opens enrollment

NCT07167862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).

The record links to 0 conditions, and to 3 interventions - of which Oral furosemide is the first listed.

NCT07167862 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07167862 about?

NCT07167862 is a clinical study titled "Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound". This study explores a novel approach to improving care for postpartum patients with preeclampsia, a pregnancy-related condition characterized by high blood pressure, protein in the urine, and organ dysfunction. Preeclampsia affects up to 9% of pregnancies and can progress to include complications of...

What is the current status of trial NCT07167862?

This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2026-06-15. Estimated completion is 2028-06-15.

What interventions are being tested in trial NCT07167862?

The interventions under investigation include: Oral furosemide (DRUG), Butterfly iQ3 ultrasound system for determination of postpartum volume status (DIAGNOSTIC_TEST), Intravenous furosemide (DRUG).

Who is sponsoring clinical trial NCT07167862?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07167862's enrollment target sits among peer trials

96 863rd of 2000 higher than 1,132 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07167862, the US trial registry maintained by the National Library of Medicine. NCT07167862 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.